TRDA
NASDAQ · Biotechnology
Entrada Therapeutics Inc
$6.87
+0.00 (+0.00%)
Analyst Consensus
Strong Buy
14
Analysts
Moderate
Coverage
Price Target
Analyst Price Target
+162.6% upside
Low Target
$12.20
Average Target
$18.04
High Target
$27.27
Current Price
$6.87
Current
$6.87
$6.87
Target
$18.04
$18.04
$12.20
$18.04 avg
$27.27
Scenario Analysis
Bear Case
$12.20
77.6%
Low target
Base Case
$18.04
+162.6%
Avg target
Bull Case
$27.27
+296.9%
High target
Risk/Reward
3.8x
Highly favorable
Price in Context
52-Week High
$16.45
-58.2% from high
52-Week Low
$4.93
+39.4% from low
Target vs 52W High
$18.04
+9.7% vs high
Next Earnings Report
Aug 12, 2026 · Before Market Open
3d
until earnings
EPS Est: $-1.07
Earnings in 3 days. Analyst targets may shift significantly after the report.
Peer Consensus — Biotechnology
| Stock | Consensus | Analysts | Buy % | Target | Upside |
|---|---|---|---|---|---|
| ABBV | Strong Buy | 39 | 79% | $257.58 | +4.7% |
| AMGN | Hold | 43 | 49% | $190.87 | -53.6% |
| GILD | Strong Buy | 37 | 81% | $362.68 | +172.3% |
| VRTX | Strong Buy | 40 | 83% | $438.34 | -11.6% |
| REGN | Buy | 38 | 71% | $76.80 | -90.2% |
| NTRA | Strong Buy | 30 | 87% | $142.91 | -55.6% |
| RVMD | Strong Buy | 29 | 93% | $114.11 | -44.4% |
| BIIB | Buy | 44 | 64% | $91.45 | -56.0% |